Introduction
============

Antibiotic dosing for patients with acute renal failure receiving continuous renal replacement therapy (CRRT) is a clinical challenge. The aim of this study was to investigate the pharmacokinetics of meropenem (M) during CRRT.

Methods
=======

A prospective and multicenter study was conducted at seven hospitals. Fifteen critically ill patients undergoing either continuous venovenous hemofiltration (CVVHF) or hemodiafiltration (CVVHDF) were included. Serum and ultrafiltrate (UF) levels of M were determined by liquid chromatography. Blood samples were drawn 24 hours after starting CRRT at 08:00 a.m., 09:00 a.m., 10:00 a.m., 01:00 p.m., 06:00 p.m., 20:00 p.m. and 08:00 a.m. of the following day. CRRT clearance (Cl), total amount of M in the UF (MUF), percentage of the dose extracted by CRRT (EF) and the AUC (ng/hour/ml) were calculated.

Results
=======

Nine patients were treated with CVVHDF and six with CVVHF. M (0.5 to 2 g) was administered every 6 to 12 h by i.v. infusion over 15 minutes. Data (mean and SD) concerning the dialysate flow rate (DF; ml/hour), blood flow rate (ml/minute) and the average UF rate (ml/ kg/hour) for CRRT techniques are shown in Table [1](#T1){ref-type="table"}. Pharmacokinetic parameters for M are depicted in Table [2](#T2){ref-type="table"}. No differences in either EF or M Cl between the two CRRT techniques were observed.

###### 

Parameters of CRRT techniques

                    CVVHF (*n*= 6)   CVVHDF (*n*= 9)
  ----------------- ---------------- -----------------
  DF rate                            964/94
  Blood flow rate   190/33           187/29
  UF rate           37.7/5.7         29.8/15.6

###### 

Pharmacokinetic parameters for meropenem

                   CVVHF     CVVHDF
  ---------------- --------- ---------
  AUC              357/188   433/369
  M dose (g/day)   1.7/0.4   2.2/1.4
  MUF (mg)         338/104   625/499
  EF (%)           28/13     30/26
  M Cl (l/hour)    1.2/0.7   1.7/1.5

Conclusion
==========

A significant removal of M by CVVHF/CVVHDF was observed. Dose adjustment is necessary in critically ill patients receiving CRRT.

Acknowledgement
===============

Supported by EC 81/00469.
